LivaNova
LIVN
About: UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Employees: 2,900
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
28% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 81
17% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 36
17% more capital invested
Capital invested by funds: $2.11B [Q1] → $2.46B (+$349M) [Q2]
1.29% more ownership
Funds ownership: 98.77% [Q1] → 100.07% (+1.29%) [Q2]
1% more funds holding
Funds holding: 249 [Q1] → 252 (+3) [Q2]
84% less call options, than puts
Call options by funds: $360K | Put options by funds: $2.28M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Needham
Mike Matson
|
$64
|
Buy
Reiterated
|
3 Sep 2025 |
|
Barclays
Matt Miksic
|
$58
|
Equal-Weight
Maintained
|
21 Aug 2025 |
Financial journalist opinion
Based on 5 articles about LIVN published over the past 30 days
